Cardiac overexpression of human VEGF165 by recombinant Semliki Forest virus leads to adverse effects in pressure-induced heart failure

Netherlands Heart Journal

Volumn 15, Issue 10, 2007, Pages 335-341

  Loot, A E ^a,b   Roks, A J M ^a,c   Westermann, D ^d   Orzechowski, H D ^d   Tschope C ^d   Wilschut, J C ^a   Tio, R A ^a   Van Gilst, W H ^a   Henning, R H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GOETHE UNIVERSITY   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; Heart failure; Hypertension; Semliki Forest virus; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN 165;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CAPILLARY; HEART OUTPUT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RAT; SEMLIKI FOREST ALPHAVIRUS; SYSTOLE; TRANSGENE; TRANSGENIC RAT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 36749025146     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03086011     Document Type: Article

References (27)

1. Loot AE, Henning RH, Deelman LE, et al. Semliki Forest virus is an efficient and selective vector for gene delivery in infarcted rat heart. J Mol Cell Cardiol 2004;37:137-42.
2. Anversa P, Ricci R, Olivetti G. Coronary capillaries during normal and pathological growth. Can J Cardiol 1986;2:104-13.
3. Anversa P, Capasso JM, Sonnenblick EH, et al. Mechanisms of myocyte and capillary growth in the infarcted heart. Eur Heart J 1990;11(Suppl B):123-32.
4. Lei L, Zhou R, Zheng W, et al. Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the post-infarcted heart. Circulation 2004;110:796-802.
5. Friehs I, del Nido PJ. Increased susceptibility of hypertrophied hearts to ischemic injury. Ann Thorac Surg 2003;75:S678-84.
6. Ashruf JF, Ince C, Bruining HA. Regional ischemia in hypertrophic Langendorff-perfused rat hearts. Am J Physiol 1999;277:H1532-9.
7. Siddiqui AJ, Blomberg P, Wardell E, et al. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophys Res Commun 2003;310:1002- 9.
8. Sylven C, Sarkar N, Wardell E, et al. Protein and angiogenic dose-response expression of phVEGF-A(165) gene in rat myocardium. J Thromb Thrombolysis 2001;12:151-6.
9. Pinto YM, Buikema H, van Gilst WH, et al. Cardiovascular endorgan damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med 1997;75:371-7.
10. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley, L, Asahara, T, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4.
11. Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease 12-month follow-up: Angiogenic gene therapy. J Intern Med 2001;250:373-81.
12. Berglund P, Sjoberg M, Garoff H, et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology 1993;11:916-20.
13. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Therapy 2000;7:1859-66.
14. Walther T, Steendijk P, Westermann D, et al. Angiotensin deficiency in mice leads to dilated cardiomyopathy. Eur J Pharmacol 2004;493: 161-5.
15. Bachmann S, Peters J, Engler E, et al. Transgenic rats carrying the mouse renin gene - morphological characterization of a low-renin hypertension model. Kidney Int 1992;41:24-36.
16. White FC, Witzel G, Breisch EA, et al. Regional capillary and myocyte distribution in normal and exercise trained male and female rat hearts. Am J Cardiovasc Pathol 1988;2:247-53.
17. Stoker ME, Gerdes AM, May JF. Regional differences in capillary density and myocyte size in the normal human heart. Anat Rec 1982;202:187- 91.
18. Gerdes AM, Callas G, Kasten FH. Differences in regional capillary distribution and myocyte sizes in normal and hypertrophic rat hearts. Am J Anat 1979;156:523-31.
19. Su H, Joho S, Huang Y, et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci USA 2004;101:16280-5.
20. Rutanen J, Rissanen TT, Markkanen JE, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109:1029-35.
21. Tio RA, Tkebuchava T, Scheuermann TH, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999;10:2953-60.
22. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47:887-93.
23. Schwarz ER, Speakman MT, Patterson M, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J Am Coll Cardiol 2000;35:1323-30.
24. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49:568-81.
25. Voisine P, Bianchi C, Ruel M, et al. Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor. Surgery 2004;136:407-15.
26. Ruel M, Wu GF, Khan TA, et al. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation 2003;108(Suppl 1):II335-40.
27. Voisine P, Bianchi C, Khan TA, et al. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction. J Thorac Cardiovasc Surg 2005;129:1414-20.